Advertisement

Most Recent

image: Best Places to Work Industry, 2012

Best Places to Work Industry, 2012

By | June 1, 2012

Much has changed in the 10 years since our first survey of industry researchers. Large companies are now looking to small, nimble ones for services as well as innovation.

0 Comments

image: Targeting DNA

Targeting DNA

By | June 1, 2012

After 20 years of high-profile failure, gene therapy is finally well on its way to clinical approval.

12 Comments

image: Underground Supermodels

Underground Supermodels

By | June 1, 2012

What can a twentysomething naked mole-rat tell us about fighting pain, cancer, and aging?

12 Comments

image: Data Diving

Data Diving

By | May 1, 2012

What lies untapped beneath the surface of published clinical trial analyses could rock the world of independent review.

28 Comments

image: Freezing Time

Freezing Time

By | May 1, 2012

Targeting the briefest moment in chemistry may lead to an exceptionally strong new class of drugs.

15 Comments

image: Telomeres in Disease

Telomeres in Disease

By | May 1, 2012

Telomeres have been linked to numerous diseases over the years, but how exactly short telomeres cause diseases and how medicine can prevent telomere erosion are still up for debate.

16 Comments

image: Are Cancer Stem Cells Ready for Prime Time?

Are Cancer Stem Cells Ready for Prime Time?

By | April 1, 2012

A flood of new discoveries has refined our definition of cancer stem cells. Now it’s up to human clinical trials to test if they can make a difference in patients.

48 Comments

image: Deliberating Over Danger

Deliberating Over Danger

By | April 1, 2012

The creation of H5N1 bird flu strains that are transmissible between mammals has thrown the scientific community into a heated debate about whether such research should be allowed and how it should be regulated.

16 Comments

image: What it Takes to Develop Better Drugs for Kids

What it Takes to Develop Better Drugs for Kids

By | March 1, 2012

Over the past 15 years, new laws and regulations in the United States and the European Union have expanded to require the inclusion of pediatric patients in clinical drug trials.  

2 Comments

image: Are the Kids Alright?

Are the Kids Alright?

By | March 1, 2012

Two key pieces of legislation, enacted to spur drugmakers into testing pharmaceutical products in children, are up for reauthorization in the US Congress this October. Have they done their jobs?

6 Comments

Follow The Scientist

icon-facebook icon-linkedin icon-twitter icon-vimeo icon-youtube
Advertisement

Stay Connected with The Scientist

  • icon-facebook The Scientist Magazine
  • icon-facebook The Scientist Careers
  • icon-facebook Neuroscience Research Techniques
  • icon-facebook Genetic Research Techniques
  • icon-facebook Cell Culture Techniques
  • icon-facebook Microbiology and Immunology
  • icon-facebook Cancer Research and Technology
  • icon-facebook Stem Cell and Regenerative Science
Advertisement
The Scientist
The Scientist
Advertisement
The Scientist
The Scientist
Life Technologies